| Old Articles: <Older 8031-8040 Newer> |
|---|
 |
The Motley Fool
June 23, 2005
Seth Jayson |
Fool by Numbers: FedEx FY 2005 The delivery company released its earnings for fiscal year 2005: Income Statement Highlights... Balance Sheet Highlights... Margin Checkup... Cash Flow Highlights...   |
The Motley Fool
June 23, 2005
Seth Jayson |
Fool by Numbers: FedEx Q4 2005 The delivery company released fourth-quarter earnings for fiscal year 2005: Income Statement Highlights... Balance Sheet Highlights... Margin Checkup... Cash Flow Highlights... |
The Motley Fool
June 23, 2005
Mike Cianciolo |
Bed Bath & Way Beyond The household products retailer shows strong earnings and sales growth, but once again gets knocked by Wall Street. |
The Motley Fool
June 23, 2005
Seth Jayson |
Fool by Numbers: Rite Aid Q1 2006 The retail pharmacy released first quarter fiscal year 2006 earnings: Income Statement Highlights... Balance Sheet Highlights... Margin Checkup... Cash Flow Highlights... |
The Motley Fool
June 23, 2005
Stephen D. Simpson |
CNOOC Knocks on Unocal's Door China's CNOOC offers cash for Unocal, but it might not be enough. Given that many U.S. politicians are already annoyed at China over other matters, it wouldn't surprise me if they move to block this deal. |
The Motley Fool
June 23, 2005
Stephen D. Simpson |
A.G. Edwards Continues to Evolve Efforts to build up the asset-management business should bring greater long-term stability. Though the stock doesn't look like a compelling bargain today, the company is improving itself. |
The Motley Fool
June 23, 2005
Brian Gorman |
Amgen's Drug-Approval Dilemma A recent lawsuit illustrates drugmakers' difficult position. Even conservative drug-stock investors could be in for a bumpy ride. |
The Motley Fool
June 23, 2005
John Reeves |
Fool by Numbers: Herman Miller 2005 The office furniture maker released 2005 earnings: Income Statement Highlights... Balance Sheet Highlights... Margin Checkup... |
The Motley Fool
June 23, 2005
Rich Smith |
Dueling Fools: Merck Bull Rebuttal Priced at a P/E of 13 and paying you a 4.8% dividend, Merck isn't just affordable -- it's a stock you can't afford not to own. |
The Motley Fool
June 23, 2005
Stephen D. Simpson |
Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects. |
| <Older 8031-8040 Newer> Return to current articles. |
